III 期伴纵隔淋巴结侵犯非小细胞肺癌中铂类药物敏感性的多态性。
Platinum Drug Sensitivity Polymorphisms in Stage III Non-small Cell Lung Cancer With Invasion of Mediastinal Lymph Nodes.
机构信息
Center of Digestive Diseases and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Department of Pathology, Hôpital Cochin, AP-HP, Université de Paris, Paris, France.
出版信息
Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):587-595. doi: 10.21873/cgp.20215.
BACKGROUND/AIM: Patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) with no progression after induction chemotherapy are usually selected for surgery. Nowadays, response to chemotherapy is not predictable. We aimed to identify genomic predictive markers for response to induction chemotherapy in stage IIIA (N2) NSCLC patients.
PATIENTS AND METHODS
Whole-exome sequencing (WES) was performed on samples from 11 patients with no response after induction chemotherapy and 6 patients with documented pathological response, admitted to the Hotel Dieu Hospital, Paris or Allegemeines Krakenhaus University, Vienna.
RESULTS
A higher alternative allele frequency was found on SENP5, rs63736860, rs1602 and NCBP2, rs553783 in the non-responder group, and on RGP1, rs1570248, SLFN12L, rs2304968, rs9905892, and GBA2, rs3833700 in the responder group.
CONCLUSION
These polymorphisms contribute to inter-individual sensibility to chemotherapy response. Interrogation of these genetic variations may have potential applicability when deciding the treatment strategy for patients with stage III NSCLC (N2).
背景/目的：诱导化疗后无进展的 IIIA（N2）期非小细胞肺癌（NSCLC）患者通常选择手术。如今，对化疗的反应不可预测。我们旨在确定 IIIA（N2）期 NSCLC 患者对诱导化疗反应的基因组预测标志物。
患者和方法
对来自巴黎圣母院医院或维也纳阿勒格梅因克劳肯豪斯大学的 11 名诱导化疗后无反应和 6 名有记录的病理反应患者的样本进行全外显子组测序（WES）。
结果
在无反应组中，SENP5、rs63736860、rs1602 和 NCBP2、rs553783 的替代等位基因频率更高，而在反应组中，RGP1、rs1570248、SLFN12L、rs2304968、rs9905892 和 GBA2、rs3833700 的替代等位基因频率更高。
结论
这些多态性导致了个体对化疗反应的敏感性不同。当决定 III 期 NSCLC（N2）患者的治疗策略时，这些遗传变异的检测可能具有潜在的适用性。
Zotero 插件